This study compares 
This study compares the minimum inhibitory concentrations of cefoperazone, cefotaxime, and moxalactam (LY127935) for 446 aerobic gram-negative bacillary isolates and further compares the minimum inhibitory concentrations of LY127935 and these third-generation cephalosporins with those of thienamycin for Pseudomonas aeruginosa. Each antibiotic at low concentrations inhibited nearly all Enterobacteriaceae tested. Minimum inhibitory concentrations for P. aeruginosa were higher, but for a majority of strains they fell below achievable serum levels. Thienamycin and cefoperazone showed significantly greater antipseudomonal activity than did cefotaxime or LY127935. Cefoxitin-inducible resistance to LY127935 and the two cephalosporins was demonstrated among Enterobacter species but did not occur with thienamycin.
Refinements in the chemistry of the cephalosporins have provided a third generation in this family of antimicrobial agents. Although secondgeneration cephalosporins-cefoxitin, cefamandole, and cefuroxime-inhibit the majority of Enterobacteriaceae, they have little or no activity against Pseudomonas aeruginosa. Third-generation compounds now being tested include cefoperazone (T1551) (5) and cefotaxime (HR756) (1, 2, 3, 8) . Moxalactam (LY127935) (4) and another new beta-lactam antimicrobial agent, thienamycin (11), though not cephalosporins, resemble them in that spectrum of activity and are currently under study. The purpose of the present study was to compare and contrast the in vitro efficacy of these four antibiotics against aerobic gram-negative bacilli isolated in the clinical laboratory of a large teaching hospital.
MATERIALS AND METHODS
We determined minimum inhibitory concentrations (MICs) by agar dilution by the procedure of Washington and Barry (9) .
Preparation of inoculum. Aerobic, gram-negative bacilli isolated by the Duke Clinical Microbiology Laboratory were streaked on nutrient agar (Difco Laboratories) to provide single colonies. After incubation and inspection for purity, plates were held at 4°C until used. Approximately five colonies were touched with a bacteriological loop and inoculated into tubes containing 2 to 5 ml of tryptic soy broth, which were incubated at 350C in air for 2 to 5 h. Turbidity was adjusted to that of a 0.5 MacFarlane standard by addition of further tryptic soy broth, the suspension was blended in a Vortex mixer, and a final dilution of 1:20 tained by using an inoculum of 106 organisms for 34% of isolates tested for susceptibility to cefoperazone, 19% in the case of cefotaxime, and 13% with LY127935. For a few isolates among E. coli, S. marcescens, E. cloacae, and Citrobacter freundii species, the inoculum effect was striking for one or more of the cephalosporins. For example, three strains ofE. coli that were inhibited by cefoperazone at 2 to 16 ,ug/ml with an inoculum of 104 were resistant to cefoperazone at 64 jLg/ml at an inoculum of 106 CFU. These same three organisms showed either no change or only a twofold increase in resistance to cefotaxime and LY127935 at the higher inoculum. Conversely, a few isolates showed a greater inoculum effect with LY127935 or cefotaxime than with cefoperazone; the MIC of cefoperazone for one strain of Citrobacter freundii showed a fourfold increase, using 106 CFU, whereas MICs of LY127935 and cefotaxime increased 64-and 128-fold, respectively. We could discern no specific relationship between the MIC determined by using 104 organisms and the magnitude of the inoculum effect.
Cefoxitin-inducible resistance. We tested for cefoxitin-inducible resistance in three strains of E. cloacae, one E. aerogenes, two Serratia marcescens, and one strain each of K. oxytoca, Providencia stuartii, Providencia rettgeri, and Morganella morganii, using the screening method devised by Waterworth Effect of serum on MICs. To estimate the importance of protein binding, we determined the MICs of the three cephalosporins for three control organisms (S. aeureus ATCC 25923, E. coli ATCC 25922, and P. aeruginosa ATCC 27853) in both Mueller-Hinton broth and in the same medium plus 50% inactivated human serum, using a standard microdilution procedure (7). The inoculum used was 105 CFU/ml. MICs of these antibiotics for S. aureus increased twoto eightfold in 50% serum. On two separate determinations, we found four-and eightfold increases in the MIC of cefoperazone against this organism, compared with two-and fourfold increases in the case of LY127935 and fourfold increases in the case of cefotaxime. Against E. coli, MICs were either unchanged or increased only twofold. MICs for this strain of P. aeruginosa showed either no change or two-to fourfold reduction in 50% serum.
Bactericidal activity. To determine the minimum bactericidal concentrations (MBCs) of the cephalosporins for control organisms, we used the microdilution procedure and subsequently plated 0.01 ml onto agar from those wells that did not show turbidity after overnight incubation in air at 350C. After further overnight incubation, the MBC was read as the least concentration of antibiotic permitting growth of five or fewer colonies. For E. coli and S. aureus, the MBC of each antibiotic was the same as its MIC. For P. aeruginosa, the MBC of LY127935 (32 ,ug/ml) was 4 times its MIC, that of cefotaxime (64 ,ug/ml) was 8 times its MIC, and that of cefoperazone (>64 ,ug/ml) was more than 16 times greater than its MIC. DISCUSSION The third generation of cephalosporins, now being evaluated, includes cefoperazone and ce-VOL. 17, 1980 all potentially useful for treatment of severe bacterial infections, because each has a remarkably wide spectrum of antibacterial activity and each is likely to prove as free from toxicity as well-tried predecessors in the ,B-lactam series. Recent reports have documented the in vitro activities of these new agents and compared them with other antimicrobial agents (1,2,3,4,5,8,11 ). Here we compare all four in a single study of 446 aerobic gram-negative isolates from the clinical microbiology laboratory of a teaching hospital.
Our findings confirm that the third-generation cephalosporins, cefoperazone and cefotaxime, as well as the f8-lactam LY127935, are highly active against the majority of Enterobacteriaceae, inhibiting at 2 ,ug/ml, over 90% of strains. This represents a significant increase in both spectrum and potency over previous generations of cephalosporins. Although P. aeruginosa isolates were relatively resistant compared with most Enterobacteriaceae, the high serum levels achievable with these new antimicrobial agents exceed MICs for the majority of this species.
Thienamycin, a noncephalosporin ,B-lactam antibiotic, was the most effective of the four agents studied against P. aeruginosa. For this species, cefoperazone also was somewhat more active than either LY127935 or cefotaxime. On the other hand, LY127935 and cefotaxime held an advantage over cefoperazone against most Enterobacteriaceae, but since this difference became inapparent at concentrations well below serum levels achievable with LY127935 or either of the two cephalosporins, its significance is uncertain.
Because Pseudomonas strains comprise an important proportion of resistant isolates, we compared MICs of the four new antibiotics for P. aeruginosa isolates that were resistant to carbenicillin, or were resistant to gentamicin or tobramycin or both by disk testing. At an arbitrary break point of 32 ,ug/ml, thienamycin inhibited all resistant strains, whereas cefoperazone inhibited 88 and 94% of carbenicillin and aminoglycoside-resistant strains, respectively. On the other hand, cefotaxime and LY127935 inhibited half or fewer of these resistant isolates at 32 ,ug/ml. In this series of clinical isolates, the proportion of gram-negative bacilli inhibited by these new agents was comparable to that sensitive to gentamicin or tobramycin. However, for P. aeruginosa, amikacin inhibited significantly more strains than any other tested except thienamycin.
Although the aminoglycosides were equivalent to or, in the case of amikacin, superior to ANTIMICROB. AGENTS CHEMOTHER.
LY127935 and the third-generation cephalosporins with respect to the percentage of aerobic gram-negative bacilli inhibited, most aminoglycoside-resistant isolates, including those resistant to amikacin, were nevertheless susceptible to one or more of the cephalosporins or LY127935. Moreover, the disparities between MICs of LY127935, cefoperazone, and cefotaxime for particular isolates indicates that no one ofthese agents has an overall advantage. Clinical microbiology laboratories will find it necessary to determine the susceptibilities of isolates to each rather than adopt a generic disk.
Cefoxitin can induce resistance in vitro to cefuroxime and cefotaxime (10) , and to cefamandole (6) , among some strains of Enterobacteriaceae. We found that cefoxitin similarly induced resistance to LY127935 and cefoperazone in four strains of Enterobacter. In contrast, cefoxitin did not induce resistance to thienamycin in these same strains. In this respect, thienamycin may possess an advantage over LY127935 and the cephalosporins.
Cefoxitin-inducible resistance is especially prevalent among Enterobacter species. It may prove to be of clinical significance because those organisms exhibiting this phenomenon also contain a subpopulation of mutants that are naturally resistant to all cephalosporins tested (10) . In our study, some but not all strains showing cefoxitin-inducible resistance appeared considerably more resistant to LY127935 and the thirdgeneration cephalosporins when 10i rather than 104 CFU were used as the inoculum. However, not all isolates for which MICs increased markedly at the higher inoculum showed enhanced resistance in the presence of cefoxitin.
We found little change in the MICs of LY127935 and the two cephalosporins for most of 47 isolates when tested at an inoculum of 106 in addition to 104 CFU. The MICs of cefoperazone were most affected, and those of LY127935 least often showed significant change. Individual organisms showed a marked inoculum effect which generally applied to one or two, but not all, of the cephalosporins and LY127935. No single agent emerged as superior for all organisms tested.
The addition of 50% heat-inactivated serum to broth lowered the MICs of LY127935 and the two cephalosporins for P. aeruginosa ATCC 27853, but raised those for S. aureus ATCC 25923 two-to eightfold, an extent in keeping with protein binding reported by the manufacturers of these agents: 50% for LY127935, 36 to 50% for cefotaxime, and 85 to 90% for cefoperazone.
LY127935 and the two cephalosporins were bactericidal for S. aureus ATCC 25923 and E. 
